Abstract:Osteosarcoma is the most common malignant bone tumour, with a peak incidence :in children and young adolescents, suggesting a role of rapid bone growth in its pathogenesis. The Wnt/beta-catenin pathway plays a crucial role in skeletal development and is indispensable for osteoblasts' lineage determination. Previous studies suggesting an oncogenic role for the Wnt/beta-catenin pathway in osteosarcoma were based on cytoplasmic staining of beta-catenin or the detection of one component of this pathway. However, those approaches are inappropriate to address whether the Wnt/beta-catenin pathway is functionally active. Therefore, in this study, we examined nuclear beta-catenin expression in 52 human osteosarcoma biopsies, 15 osteoblastomas (benign bone tumours), and four human osteosarcoma cell lines by immunohistochemistry. Furthermore, we modulated Wnt/beta-catenin pathway activity using a GIN (GSK3 beta inhibitor) and evaluated its effect on cell growth and osteogenic differentiation. Absence of nuclear beta-catenin staining was found in 90% of the biopsies and all osteosarcoma cell lines, whereas strong nuclear beta-catenin staining was observed in all osteoblastomas. Wnt-luciferase activity was comparable to the negative control in all osteosarcoma cell lines. GIN stimulated the Wnt/beta-catenin pathway, as shown by translocation of beta-catenin into the nucleus and increased Wnt-luciferase activity as well as mRNA expression of AXIN2, a specific downstream target gene. Stimulation of the Wnt/beta-catenin pathway by GIN significantly reduced cell proliferation in the cell lines MG-63 and U-2-OS and enhanced differentiation in the cell lines HOS and SJSA-1, as shown by an increase in alkaline phosphatase (ALP) activity and mineralization. In contrast with the oncogenic role of the Wnt/beta-catenin pathway in osteosarcoma as previous studies suggested, here we demonstrate that this pathway is inactivated in osteosarcoma. Moreover, activation of the Wnt/beta-catenin pathway inhibits cell proliferation or promotes osteogenic differentiation in osteosarcoma cell lines. Our data suggest that loss of Wnt/beta-catenin pathway activity, which is required for ostcoblast differentiation, may contribute to osteosarcoma development. Copyright (C) 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Wnt/β‐Catenin Signaling Activates Expression of the Bone‐Related Transcription Factor RUNX2 in Select Human Osteosarcoma Cell Types

MicroRNA-211 inhibits tumor growth and invasion through directly targeting RUNX 2 in osteosarcoma

Transcriptional Regulation of Runx2 by HSP90 Controls Osteosarcoma Apoptosis Via the AKT/GSK‐3β/β‐catenin Signaling

Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone

Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response in Osteosarcoma

RUNX2 (6p21.1) amplification in osteosarcoma

The Cancer‐related Transcription Factor Runx2 Combined with Osteopontin: a Novel Prognostic Biomarker in Resected Osteosarcoma

Bone Morphogenetic Protein‐2 Promotes Osteosarcoma Growth by Promoting Epithelial‐mesenchymal Transition (EMT) Through the Wnt/β‐catenin Signaling Pathway

Inactive Wnt/Beta-Catenin Pathway in Conventional High-Grade Osteosarcoma

Decreased WWOX Expression Promotes Angiogenesis in Osteosarcoma.

Targeting the Wnt/β-catenin pathway in human osteosarcoma cells

RUNX2 as a promising therapeutic target for malignant tumors

RUNX2 promotes the suppression of osteoblast function and enhancement of osteoclast activity by multiple myeloma cells

NKX2-2 Suppresses Osteosarcoma Metastasis and Proliferation by Downregulating Multiple Target Genes.

Cmar_a_302173 2539..2548

Two of four alternatively spliced isoforms of RUNX2 control osteocalcin gene expression in human osteoblast cells

Myeloma cell-derived Runx2 promotes myeloma progression in bone.

MiR-302b Suppresses Osteosarcoma Cell Migration and Invasion by Targeting Runx2

Exploring the Interplay of RUNX2 and CXCR4 in Melanoma Progression

Inhibition of the Wnt-β-catenin and Notch Signaling Pathways Sensitizes Osteosarcoma Cells to Chemotherapy.

High Expression of XRCC6 Promotes Human Osteosarcoma Cell Proliferation Through the Β-Catenin/wnt Signaling Pathway and is Associated with Poor Prognosis